Back to News
Market Impact: 0.2
Eli Lilly Expands Gate Bioscience Molecular Gates Collaboration
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
Eli Lilly expanded its collaboration and license agreement with Gate Bioscience to discover and develop molecular gate therapeutics. The expansion adds one target and gives Lilly the option to add a second; no financial terms were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
LLY0.45
More News
- Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction
- Samsung, SK Hynix shares drop as Q3 earnings loom
- DeepSeek set to raise at least $12 bln in Tencent, CATL-led round- Bloomberg
- Security researcher claims to they found KVM guest-host escape flaw
- Brazil Election: Bolsonaro Pushes Lula to Brink as Markets Set to Rally
- SpaceX stock climbs to highest since June, returning Musk to trillionaire status
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect
- Fintool Alternatives After the Microsoft Acquisition